BioCentury
ARTICLE | Strategy

Takeda hits the gas

Why Takeda says Shire accelerates execution of Weber’s globalization strategy

May 11, 2018 10:55 PM UTC

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management.

On May 8, after two months and several rejected bids, Shire accepted Takeda’s proposed takeout offer of £46 billion ($62 billion). The consideration is a 46/54 split between cash and stock, comprised of $30.33 in cash per Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs. Takeda closed at ¥4,638 ($42.67) in Tokyo on May 8 before the final deal terms were announced. Takeda shareholders will own about 50% of the combined company...